212 related articles for article (PubMed ID: 34727329)
1. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study.
Hashimoto Y; Ito T; Gotoh A; Nakamae M; Kimura F; Koike M; Kirito K; Wada H; Usuki K; Tanaka T; Mori T; Wakita S; Saito TI; Kada A; Saito AM; Shimoda K; Sugimoto Y; Kurokawa T; Tomita A; Edahiro Y; Akashi K; Matsumura I; Takenaka K; Komatsu N
Int J Hematol; 2022 Feb; 115(2):208-221. PubMed ID: 34727329
[TBL] [Abstract][Full Text] [Related]
2. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
[TBL] [Abstract][Full Text] [Related]
3. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
[TBL] [Abstract][Full Text] [Related]
4. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Rotunno G; Mannarelli C; Guglielmelli P; Pacilli A; Pancrazzi A; Pieri L; Fanelli T; Bosi A; Vannucchi AM;
Blood; 2014 Mar; 123(10):1552-5. PubMed ID: 24371211
[TBL] [Abstract][Full Text] [Related]
5. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
Ochiai T; Yasuda H; Araki M; Misawa K; Morishita S; Nudejima M; Hironaka Y; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Eur J Haematol; 2018 Jun; 100(6):544-549. PubMed ID: 29405428
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
[TBL] [Abstract][Full Text] [Related]
9. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pósfai É; Marton I; Király PA; Kotosz B; Kiss-László Z; Széll M; Borbényi Z
Pathol Oncol Res; 2015 Jul; 21(3):751-8. PubMed ID: 25573593
[TBL] [Abstract][Full Text] [Related]
11. [Gene mutation spectrum and clinical characteristics analysis of 178 patients with essential thrombocytosis].
Dong H; Fu RF; Ju MK; Sun T; Liu XF; Xue F; Chi Y; Yang RC; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):837-842. PubMed ID: 31775483
[No Abstract] [Full Text] [Related]
12. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
13. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
14. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
15. Essential Thrombocythemia: One-Center Data in a Changing Disease.
Pirciulescu N; Gaman MA; Mihailescu M; Constantin C; Dragomir M; Dobrea C; Costache S; Ursuleac I; Coriu D; Crisan AM
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557000
[TBL] [Abstract][Full Text] [Related]
16. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
[TBL] [Abstract][Full Text] [Related]
17. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
Diep R; Metjian A
J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
[TBL] [Abstract][Full Text] [Related]
18. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
19. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
[TBL] [Abstract][Full Text] [Related]
20. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]